We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMC's Tremisia Fungicide Debuts in EMEA Region After Approvals
Read MoreHide Full Article
Key Takeaways
FMC debuts Tremisia fungicide in Ukraine, its first fluindapyr product launch in the EMEA region.
The approval grants FMC access to over 10M hectares of Ukrainian farmland for commercialization.
Fluindapyr helps control Alternaria, Sclerotinia, Septoria and rust in sunflower and wheat crops.
FMC Corporation (FMC - Free Report) introduced its novel fluindapyr technology upon approval of Tremisia fungicide in Ukraine. This marks the first launch of such technology in the EMEA region. This would act as a tool for growers to combat significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat.
The registration paved the way for the commercialization of FMC’s most advanced fungicide technology. Ukraine being the world's largest exporters of sunflower, oilseed rape, and wheat, the solution best suits the Ukrainian growers to fill the gap in disease management options. They are now presented with the choice of a best-in-class solution to overcome pressure from diseases.
The approval opens FMC to more than 10 million hectares of Ukrainian farmland, following its successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea and the United States, with conditional approval secured in the Philippines earlier this year.
Earlier this month, FMC partnered with Corteva to expand the use of fluindapyr fungicide in U.S. corn and soybean markets. It was aimed to tackle tough foliar diseases like tar spot and rust. Corteva plans to launch its fluindapyr product in 2026, pending EPA regulatory approval.
The company maintained its 2025 guidance, with revenue projected at $4.15-$4.35 billion, flat at the midpoint year-over-year. Adjusted EBITDA remains at $870-$950 million, up 1% at the midpoint (4% excluding the GSS divestiture). The outlook includes $15-$20 million in added tariff costs. Adjusted EPS is unchanged at $3.26-$3.70, flat at the midpoint, and free cash flow is still expected between $200 million and $400 million.
FMC stock has declined 21.3% over the past year against the industry’s 10.3% growth.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.32 per share, indicating a 24.14% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 42.7% in the past year.
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.69 per share, implying a 20.71% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for CF’s 2025 earnings is pegged at $6.83 per share, indicating a rise of 1.34% from year-ago levels. The company’s earnings beat the consensus estimate in each of the trailing four quarters. Its shares have gained 33% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FMC's Tremisia Fungicide Debuts in EMEA Region After Approvals
Key Takeaways
FMC Corporation (FMC - Free Report) introduced its novel fluindapyr technology upon approval of Tremisia fungicide in Ukraine. This marks the first launch of such technology in the EMEA region. This would act as a tool for growers to combat significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat.
The registration paved the way for the commercialization of FMC’s most advanced fungicide technology. Ukraine being the world's largest exporters of sunflower, oilseed rape, and wheat, the solution best suits the Ukrainian growers to fill the gap in disease management options. They are now presented with the choice of a best-in-class solution to overcome pressure from diseases.
The approval opens FMC to more than 10 million hectares of Ukrainian farmland, following its successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea and the United States, with conditional approval secured in the Philippines earlier this year.
Earlier this month, FMC partnered with Corteva to expand the use of fluindapyr fungicide in U.S. corn and soybean markets. It was aimed to tackle tough foliar diseases like tar spot and rust. Corteva plans to launch its fluindapyr product in 2026, pending EPA regulatory approval.
The company maintained its 2025 guidance, with revenue projected at $4.15-$4.35 billion, flat at the midpoint year-over-year. Adjusted EBITDA remains at $870-$950 million, up 1% at the midpoint (4% excluding the GSS divestiture). The outlook includes $15-$20 million in added tariff costs. Adjusted EPS is unchanged at $3.26-$3.70, flat at the midpoint, and free cash flow is still expected between $200 million and $400 million.
FMC stock has declined 21.3% over the past year against the industry’s 10.3% growth.
Image Source: Zacks Investment Research
FMC’s Zacks Rank & Key Picks
FMC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Newmont Corporation (NEM - Free Report) , Akzo Nobel N.V. (AKZOY - Free Report) and CF Industries (CF - Free Report) . While NEM currently sports a Zacks Rank #1 (Strong Buy), AKZOY and CF carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.32 per share, indicating a 24.14% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 42.7% in the past year.
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.69 per share, implying a 20.71% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for CF’s 2025 earnings is pegged at $6.83 per share, indicating a rise of 1.34% from year-ago levels. The company’s earnings beat the consensus estimate in each of the trailing four quarters. Its shares have gained 33% in the past year.